Patent · US Expired

Styrene-isoprene-styrene copolymer-based transdermal matrix system for the administration of an oestrogen and/or a progestogen

US5580572A · kind A · utility

65Cited by
4References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 28, 1995
Grant dateDec 3, 1996
Priority date
Expiry dateMar 28, 2015

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P5/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention is concerned with a new transdermal matrix system for the percutaneous administration of a hormone, said matrix system, which has a support and a self-adhesive matrix, comprising a matrix containing: PA0 (a) 20 to 42 parts by weight of a poly(styrene-isoprene-styrene) triblock copolymer, PA0 (b) 35 to 55 parts by weight of a tackifying resin. PA0 (c) 5 to 25 parts by weight of a plasticizing agent selected from the group consisting of oleic alcohol, peglicol 5-oleate, propyleneglycol laurate or a polypropoxyl ether of cetyl alcohol, PA0 (d) 5 to 15 parts by weight of at least one compound selected from the group consisting of: PA1 crotamiton, and PA1 N-substituted 2-pyrrolidones of formula I, ##STR1## wherein R represents a (C.sub.1 -C.sub.15)-alkyl, cyclohexyl or 2-hydroxyethyl group, PA0 (e) 0,01 to 1 part by weight of a stabilizing agent and, PA0 (f) 0,1 to 5 parts by weight of a hormone selected from the group consisting of oestrogen components, progestogen components and mixtures thereof. It also relates to a method for prepararing said system. No figure.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.